Treatment of adults with newly diagnosed CD33-ositive AML and for treatment of relapsed or refractory CD33-positive AML in adults and in pediatric patients 2 years and older. May be used in combination with daunorubicin and cytarabine for adults with newly diagnosed AML. This evidence concerns the gene CD33 and acute myeloid leukemia.